Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

Executive Summary

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Advertisement

Related Content

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Finance Watch: VC Tally Hits $14.5bn For 2018, Beating 2017 With A Quarter Left To Go
Venture Funding Deals: Orchard Brings Total To $291m
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
AI Drug Developer TwoXAR Raises $10m In Series A
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Venture Funding Deals: Orchard Therapeutics Spreads Its Roots
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124390

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel